Evidence map›Paper›PMID 21445845›Full record

ArticleIUBMB life2011

Ligand migration in human indoleamine-2,3 dioxygenase.

Karin Nienhaus, Elena Nickel, Changyuan Lu, Syun-Ru Yeh, G Ulrich Nienhaus

Open access · bronzeAbstract read
In one paragraph

Article in IUBMB life, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Karin NienhausKarlsruhe Institute of Technology (KIT), Institute of Applied Physics and Center for Functional Nanostructures, Karlsruhe, Germany. Karin.nienhaus@kit.edu
Elena Nickel
Changyuan Lu
Syun-Ru Yeh
G Ulrich Nienhaus
Albert Einstein College of Medicine · USIn-Q-Tel · USKarlsruhe Institute of Technology · DEUniversity of Illinois Urbana-Champaign · US

Funding

Catalytic and Inhibitory Mechanisms in Indoleamine 2,3-dioxygenaseR01GM086482 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI YEH, SYUN-RU · 2010 to 2013
$1.3M
NIGMS NIH HHS R01 GM086482
6 · The paper itself

Abstract

Human indoleamine 2,3-dioxygenase (hIDO), a monomeric heme enzyme, catalyzes the oxidative degradation of L-tryptophan (L-Trp) and other indoleamine derivatives. Its activity follows typical Michaelis-Menten behavior only for L-Trp concentrations up to 50 μM; a further increase in the concentration of L-Trp causes a decrease in the activity. This substrate inhibition of hIDO is a result of the binding of a second L-Trp molecule in an inhibitory substrate binding site of the enzyme. The molecular details of the reaction and the inhibition are not yet known. In the following, we summarize the present knowledge about this heme enzyme.

Indexed as

BiocatalysisHumansIndoleamine-Pyrrole 2,3,-DioxygenaseKineticsLigandsModels, MolecularSubstrate SpecificityIndoleamine-Pyrrole 2,3,-DioxygenaseLigands

Identifiers

PMID21445845
PMCPMC4535348
OpenAlexW2027701005

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.